Group 1 - The core point of the article is the revised articles of association of Guangxi Liuyao Group Co., Ltd. which aim to protect the rights and interests of the company, shareholders, employees, and creditors while regulating the company's organization and behavior [1][2][3] - The company was established as a joint-stock company in accordance with the Company Law and other relevant regulations, with a registered capital of RMB 397,168,905 [2][3] - The company is committed to the health industry, providing professional pharmaceutical distribution services, and aims to become an innovative enterprise in the pharmaceutical circulation field [5][6] Group 2 - The company’s business scope includes wholesale and retail of pharmaceuticals, medical device operations, and various related services [5][6] - The company has issued a total of 397,168,905 shares, all of which are ordinary shares with a par value of RMB 1 per share [7][8] - The company can increase its capital through various methods, including issuing shares to unspecified objects or existing shareholders [10][11] Group 3 - The company’s shareholders have rights to dividends, participate in shareholder meetings, and supervise the company's operations [15][16] - The company must hold an annual general meeting within six months after the end of the previous fiscal year [50][51] - The company’s articles stipulate that any significant transactions must be approved by the board and submitted to the shareholders' meeting for approval [24][26]

达嘉维康8月25日报收12.61元，较前一交易日下跌0.06元，跌幅0.47%。当日成交量为71729手，成交金 额达0.91亿元。该股开盘报12.67元，盘中最高触及12.76元，最低下探至12.52元。 8月25日主力资金净流出1718.12万元，占流通市值的0.99%。近五个交易日累计净流出3400.34万元，占 流通市值的1.96%。 风险提示：股市有风险，投资需谨慎。 达嘉维康是一家医药商业企业，业务涉及药品批发、零售及物流配送服务。公司智能物流中心采用"智 能化仓储硬件+数字化系统"技术，实现了药品流转全流程的一体化管理。 公司在投资者互动平台表示，目前业务板块暂未接入DeepSeek、ChatGPT等人工智能大模型端口，但正 在积极推进与人工智能公司、高校及科研院所的合作，探索新技术与现有业务的结合点。 ...

Core Viewpoint - Recently, Shanghai Pharmaceuticals (601607) established a new subsidiary, Up Pharmaceutical Holdings (Yongzhou) Co., Ltd., with a registered capital of 20 million yuan, indicating an expansion in its operational capabilities in the pharmaceutical sector [1] Company Summary - The new company is co-owned by Shanghai Pharmaceuticals' subsidiary, Up Pharmaceutical Holdings (Hunan) Co., Ltd., and Yongzhou Big Health Industry Co., Ltd., reflecting a strategic partnership in the health industry [1] - The business scope of the new entity includes drug wholesale, sales of Class II and III radiation devices, operation of Class III medical devices, general equipment repair, and professional design services, showcasing a diverse range of services [1]

Group 1 - The stock price of the company is reported at 8.34 yuan, down 0.04 yuan from the previous trading day, with a trading volume of 101,500 hands and a transaction amount of 85 million yuan [1] - The company's main business is in pharmaceutical commerce, covering drug wholesale and retail [1] - In the first half of 2025, the company achieved operating revenue of 5.149 billion yuan, a year-on-year increase of 3.29%, but the net profit attributable to shareholders decreased by 46.31% to 72.5792 million yuan [1] Group 2 - The decline in performance is primarily attributed to the impact of centralized procurement policies, which have pressured the gross profit margin of the wholesale business [1] - The company reported a significant increase in credit impairment losses, reaching 33.8926 million yuan in the first half of the year, with a year-on-year increase of 43.8% in the provision for bad debts on accounts receivable [1] - The latest announcement indicates that the bad debt provision ratio for accounts receivable aged 2-3 years is as high as 83.11% [1]